CNEW VanEck New China UCITS ETF

Fund Details

Base Currency	USD
Inception Date	24 September 2021
Domicile	Ireland
Net Assets	$7.3M
Shares Outstanding	470,000
Total Expense Ratio	0.60%
Product Structure	Physical (Full Replication)
UCITS Compliant	Yes
Rebalance Frequency	Semi-Annually
Distribution Frequency	None
Income Treatment	Reinvestment
Countries of Registration	AT, CH, CZ, DE, DK, ES, FI, FR, HR, HU, IE, IS, IT, LU, NL, NO, PL, PT, RO, SE, SG, UK

Index Information

Index Provider	MarketGrader
Index Type	Total Return Net
Currency	USD
Inception Date	22 Mar 2021
Reconstitution Frequency	Semi-Annually
Bloomberg Ticker	MGNCUSNR
Reuters Ticker	--

Fund Data

Number of Holdings	100
Price/Earnings Ratio*	16.42
Price/Book Ratio*	2.87
Weighted Avg. MCap	USD 22.3B

* Last 12 Months

Country Breakdown

China	96.86%
Taiwan Region	1.85%
United Kingdom	0.98%
Other/Cash	0.31%

Fund Description


30 September 2026

The VanEck New China UCITS ETF (CNEW) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MarketGrader New China Screened Index (MGNCUSNR).

Performance History (%)

Month End as of 30 Sep 2026	1 MO	3 MO	YTD	1 YR	3 YR	5 YR	10 YR	ETF INCEPTION
ETF	-3.04	-1.97	-8.97	-15.01	2.92	-5.00	--	-4.86
MGNCUSNR (Index)	-2.93	-1.86	-8.62	-14.72	3.62	-4.31	--	-4.20

Past Performance as of 31 Dec 2025



	2021	2022	2023	2024	2025
VanEck New China UCITS ETF	-27.9	-8.6	-0.5	23.5	
Benchmark Index (MarketGrader New China Screened Index)	-27.5	-7.1	0.4	23.6	

Past performance does not predict future returns. Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply. Returns may increase or decrease as a result of currency fluctuations. Investors must be aware that, due to market fluctuations and other factors, the performance of the ETFs may vary over time and should consider a medium/long-term perspective when evaluating the performance of ETFs. **Investing is subject to risks, including the possible loss of principal. Source:** VanEck.

*Reference periods indicate cumulative performance, not annualized.

CNEW VanEck New China UCITS ETF

Top 10 Holdings

30 September 2026

WUXI BIOLOGICS CAYMAN INC	1.17%
CSPC PHARMACEUTICAL GROUP LTD	1.15%
AMLOGIC SHANGHAI CO LTD	1.14%
NINGBO MENOVO PHARMACEUTICAL CO LTD	1.12%
CSPC INNOVATION PHARMACEUTICAL CO LTD	1.11%
HANSOH PHARMACEUTICAL GROUP CO LTD	1.10%
ALL WINNER TECHNOLOGY CO LTD	1.09%
WUXI APPTEC CO LTD	1.09%
NETEASE INC	1.07%
SIMCERE PHARMACEUTICAL GROUP LTD	1.07%
SUBTOTAL - TOP 10	11.12%
REMAINING HOLDINGS	88.57%
OTHER/CASH	0.31%
TOTAL	100.00%

For a complete up-to-date listing of Fund holdings, please visit www.vaneck.com

Trading Information

EXCHANGE	TRADING CURRENCY	ISIN	EXCHANGE TICKER	BLOOMBERG TICKER	REUTERS TICKER	SEDOL	IOPV SYMBOL
LONDON STOCK EXCHANGE	USD	IE0000H445G8	CNEW	CNEW LN	CNEW.L	BMGTRM5	CNEWUSIV
LONDON STOCK EXCHANGE	GBP	IE0000H445G8	CEBG	CEBG LN	CEGB.L	BP480L5	--
DEUTSCHE BÖRSE	EUR	IE0000H445G8	CNIE	CNIE GY	CNIE.DE	BP48253	CNIEEUIV
SIX SWISS EXCHANGE	CHF	IE0000H445G8	CNEW	CNEW SE	CNEW.S	BMWS500	--
BORSA ITALIANA	EUR	IE0000H445G8	CNEW	CNEW IM	CNEW.MI	BNHQTV5	--

Key Risks

Foreign Currency Risk: Because all or a portion of the Fund are being invested in securities denominated in foreign currencies, the Fund's exposure to foreign currencies and changes in the value of foreign currencies versus the Base Currency may result in reduced returns for the Fund, and the value of certain foreign currencies may be subject to a high degree of fluctuation.

Emerging Markets Risk: Investments in emerging market countries are subject to specific risks and securities are generally less liquid and less efficient and securities markets may be less well regulated. Specific risks may be heightened by currency fluctuations and exchange control; imposition of restrictions on the repatriation of funds or other assets; governmental interference; higher inflation; social, economic and political uncertainties. A further risk of investing in this ETF is that the assessment of Chinese financial reports by relevant regulators may not be adequate.

Risk of investing in smaller companies: The securities of smaller companies may be more volatile and less liquid than the securities of large companies. Smaller companies, when compared with larger companies, may have a shorter history of operations, fewer financial resources, less competitive strength, may have a less diversified product line, may be more susceptible to market pressure and may have a smaller market for their securities. This is another factor to take into consideration before investing in a China ETF.

For more information on risks, please see the “Risk Factors” section of the relevant Fund’s prospectus, available on www.vaneck.com.

IMPORTANT INFORMATION

This is marketing communication. Please refer to the prospectus of the UCITS and to the Key Information Document (“KID”) before making any final investment decisions. These documents are available in English and the KIDs in local languages and can be obtained free of charge at www.vaneck.com, from VanEck Asset Management B.V. (the “Management Company”) or, where applicable, from the relevant appointed facility agent for your country.

This information originates from VanEck (Europe) GmbH, which is authorized as an EEA investment firm under MiFID under the Markets in Financial Instruments Directive (“MiFID”). VanEck (Europe) GmbH has its registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, and has been appointed as distributor of VanEck products in Europe by the Management Company. The Management Company is incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM).

This material is only intended for general and preliminary information and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision on the basis of this information.

VanEck New China UCITS ETF (the "ETF") is a sub-fund of VanEck UCITS ETFs plc, an open-ended variable capital umbrella investment company with limited liability between sub-funds. The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. For details on the regulated markets where the ETF is listed, please refer to the Trading Information section on the ETF page at www.vaneck.com. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.

"MARKETGRADER" and “MarketGrader New China Screened Index” are trademarks of MarketGrader.com Corp. and have been licensed for use for certain purposes by

VanEck (Europe) GmbH (“VanEck”). VanEck's ETF, based on the MarketGrader New China Screened Index, is not sponsored, endorsed, sold or promoted by MarketGrader, and MarketGrader makes no representation regarding the advisability of investing in such product. It is not possible to invest directly in an index.

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data for the Irish domiciled ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Returns may increase or decrease as a result of currency fluctuations. Investors must be aware that, due to market fluctuations and other factors, the performance of the ETFs may vary over time and should consider a medium/long-term perspective when evaluating the performance of ETFs.

Investing is subject to risk, including the possible loss of principal. Investors must buy and sell units of the UCITS on the secondary market via an intermediary (e.g. a broker) and cannot usually be sold directly back to the UCITS. Brokerage fees may incur. The buying price may exceed, or the selling price may be lower than the current net asset value. The indicative net asset value (iNAV) of the UCITS is available on Bloomberg. The Management Company may terminate the marketing of the UCITS in one or more jurisdictions. The summary of the investor rights is available in English at: complaints-procedure.pdf (vaneck.com). For any unfamiliar technical terms, please refer to ETF Glossary | VanEck.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

© VanEck (Europe) GmbH